Mineralys therapeutics, inc.MLYS.US Overview
US StockHealthcare
(No presentation for MLYS)
MLYS Overall Performance
MLYS AI Analysis & Strategy
MLYS Recent Performance
1.38%
Mineralys therapeutics, inc.
0.81%
Avg of Sector
-1.14%
S&P500
MLYS PowerScanner
MLYS Key Information
MLYS Valuation Metrics
MLYS Earnings Table
MLYS Profile
Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and associated cardiovascular diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of patients with uncontrolled or resistant hypertension. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.